Top

Published in:

01-07-2020 | Myocarditis | Clinical study

Axitinib plus avelumab or pembrolizumab: management of AEs

Published in: Reactions Weekly | Issue 1/2020

Excerpt

Clinical monitoring and experience with both axitinib and immune checkpoint inhibitors (ICI) are necessary to manage adverse events (AEs) of axitinib−ICI combination therapy for first-line treatment of advanced renal cell carcinoma (RCC), which has recently been approved by the European Medicines Agemcy (EMA) and the US FDA, say authors of a Merck KGaA- and Pfizer-funded study published in the British Journal of Cancer which included a systematic review. …

Grunwald V, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer : 26 Jun 2020. Available from: URL: http://doi.org/10.1038/s41416-020-0949-9

Title: Axitinib plus avelumab or pembrolizumab: management of AEs
Publication date: 01-07-2020
Publisher: Springer International Publishing
Keywords: Myocarditis
Axitinib
Checkpoint Inhibitors
Published in: Reactions Weekly / Issue 1/2020
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-80485-5

At a glance: The STEP trials

Springer Medicine

Axitinib plus avelumab or pembrolizumab: management of AEs

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Amphotericin-B-liposomal/immunosuppressants

Factor-VIII-inhibitor-bypassing-fraction/warfarin

Heparin

Multiple drugs

BCG

Prednisone